Following positive results against template mTSP1, rh-CD47p—as a therapeutic DRP design to antagonize TSP1-initiated detrimental effects—was further investigated under experimental pathological PAH-mimicking conditions (PAH is typically marked by pre-existent excess of TSP1 in circulation) [39]. Here, ST14 is linked to pulmonary arterial hypertension.